Antibodies to watch in 2025
The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational prod...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2443538 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846111556319838208 |
|---|---|
| author | Silvia Crescioli Hélène Kaplon Lin Wang Jyothsna Visweswaraiah Vaishali Kapoor Janice M. Reichert |
| author_facet | Silvia Crescioli Hélène Kaplon Lin Wang Jyothsna Visweswaraiah Vaishali Kapoor Janice M. Reichert |
| author_sort | Silvia Crescioli |
| collection | DOAJ |
| description | The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (依達方®), and antibody–drug conjugate (ADC) sacituzumab tirumotecan (佳泰萊®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported. |
| format | Article |
| id | doaj-art-891b0e1e63db40569b2c32c3ee421af8 |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-891b0e1e63db40569b2c32c3ee421af82024-12-23T07:55:51ZengTaylor & Francis GroupmAbs1942-08621942-08702025-12-0117110.1080/19420862.2024.2443538Antibodies to watch in 2025Silvia Crescioli0Hélène Kaplon1Lin Wang2Jyothsna Visweswaraiah3Vaishali Kapoor4Janice M. Reichert5Business Intelligence Research, The Antibody Society, Inc., Framingham, MA, USATranslational Medicine Department, Institut de Recherches Internationales Servier, Gif-sur-Yvette, FranceRegeneron Formulation Development, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USADrug Creation, Seismic Therapeutic, Watertown, MA, USADepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO, USABusiness Intelligence Research, The Antibody Society, Inc., Framingham, MA, USAThe commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (依達方®), and antibody–drug conjugate (ADC) sacituzumab tirumotecan (佳泰萊®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.https://www.tandfonline.com/doi/10.1080/19420862.2024.2443538Antibody therapeuticcancerfood and drug administrationEuropean Medicines Agencyimmune-mediated disorders |
| spellingShingle | Silvia Crescioli Hélène Kaplon Lin Wang Jyothsna Visweswaraiah Vaishali Kapoor Janice M. Reichert Antibodies to watch in 2025 mAbs Antibody therapeutic cancer food and drug administration European Medicines Agency immune-mediated disorders |
| title | Antibodies to watch in 2025 |
| title_full | Antibodies to watch in 2025 |
| title_fullStr | Antibodies to watch in 2025 |
| title_full_unstemmed | Antibodies to watch in 2025 |
| title_short | Antibodies to watch in 2025 |
| title_sort | antibodies to watch in 2025 |
| topic | Antibody therapeutic cancer food and drug administration European Medicines Agency immune-mediated disorders |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2024.2443538 |
| work_keys_str_mv | AT silviacrescioli antibodiestowatchin2025 AT helenekaplon antibodiestowatchin2025 AT linwang antibodiestowatchin2025 AT jyothsnavisweswaraiah antibodiestowatchin2025 AT vaishalikapoor antibodiestowatchin2025 AT janicemreichert antibodiestowatchin2025 |